secwatch / observer
8-K filed March 29, 2024, 7:59 PM ET ticker ATXI CIK 0001644963
regulatory confidence high sentiment negative materiality 0.70

AVENUE THERAPEUTICS, INC. (ATXI): Nasdaq/NYSE listing notice — Nasdaq issues delist determination for Avenue Therapeutics; extension to May 20 granted

AVENUE THERAPEUTICS, INC.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5550(b)(2)).

Exchange
nasdaq
Notice
delisting notice
Deficiency
minimum bid price
Rules
5550(a)(2), 5810(c)(3)(A), 5550(b)(2)
Exact text from the filing
March 26, 2024, the Staff issued a delist determination with respect to the deficiency, as required by the Nasdaq Listing Rules. Notwithstanding, and as previously disclosed, on February 15, 2024, the Company attended a hearing before the Nasdaq Hearings Panel (the “Panel”), at which the Company presented its plan to evidence compliance with both the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “Equity Rule”) as well as the Bid Price Rule (together with the Bid Price Rule, the “Rules”). By decision dated March 11, 2024, the Panel granted the Company
View on SEC.gov

Browse all listing & compliance notices →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR
accession 0001437749-24-010044
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.